1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Bioresorbable Coronary Stents Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Bioresorbable Coronary Stents Market Revenue and Volume, by Material
8.1.1 Polymer
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Metal
8.1.2.1. Market Revenue and Volume Forecast
9.1. Bioresorbable Coronary Stents Market Revenue and Volume, by Drug
9.1.1. Sirolimus
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Novalimus
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast
10.1. Bioresorbable Coronary Stents Market Revenue and Volume, by End Use
10.1.1. Inpatient Facilities
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Outpatient Facilities
10.1.2.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Material
11.1.2. Market Revenue and Volume Forecast, by Drug
11.1.3. Market Revenue and Volume Forecast, by End Use
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Material
11.1.4.2. Market Revenue and Volume Forecast, by Drug
11.1.4.3. Market Revenue and Volume Forecast, by End Use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Material
11.1.5.2. Market Revenue and Volume Forecast, by Drug
11.1.5.3. Market Revenue and Volume Forecast, by End Use
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Material
11.2.2. Market Revenue and Volume Forecast, by Drug
11.2.3. Market Revenue and Volume Forecast, by End Use
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Material
11.2.4.2. Market Revenue and Volume Forecast, by Drug
11.2.4.3. Market Revenue and Volume Forecast, by End Use
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Material
11.2.5.2. Market Revenue and Volume Forecast, by Drug
11.2.5.3. Market Revenue and Volume Forecast, by End Use
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Material
11.2.6.2. Market Revenue and Volume Forecast, by Drug
11.2.6.3. Market Revenue and Volume Forecast, by End Use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Material
11.2.7.2. Market Revenue and Volume Forecast, by Drug
11.2.7.3. Market Revenue and Volume Forecast, by End Use
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Material
11.3.2. Market Revenue and Volume Forecast, by Drug
11.3.3. Market Revenue and Volume Forecast, by End Use
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Material
11.3.4.2. Market Revenue and Volume Forecast, by Drug
11.3.4.3. Market Revenue and Volume Forecast, by End Use
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Material
11.3.5.2. Market Revenue and Volume Forecast, by Drug
11.3.5.3. Market Revenue and Volume Forecast, by End Use
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Material
11.3.6.2. Market Revenue and Volume Forecast, by Drug
11.3.6.3. Market Revenue and Volume Forecast, by End Use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Material
11.3.7.2. Market Revenue and Volume Forecast, by Drug
11.3.7.3. Market Revenue and Volume Forecast, by End Use
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Material
11.4.2. Market Revenue and Volume Forecast, by Drug
11.4.3. Market Revenue and Volume Forecast, by End Use
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Material
11.4.4.2. Market Revenue and Volume Forecast, by Drug
11.4.4.3. Market Revenue and Volume Forecast, by End Use
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Material
11.4.5.2. Market Revenue and Volume Forecast, by Drug
11.4.5.3. Market Revenue and Volume Forecast, by End Use
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Material
11.4.6.2. Market Revenue and Volume Forecast, by Drug
11.4.6.3. Market Revenue and Volume Forecast, by End Use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Material
11.4.7.2. Market Revenue and Volume Forecast, by Drug
11.4.7.3. Market Revenue and Volume Forecast, by End Use
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Material
11.5.2. Market Revenue and Volume Forecast, by Drug
11.5.3. Market Revenue and Volume Forecast, by End Use
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Material
11.5.4.2. Market Revenue and Volume Forecast, by Drug
11.5.4.3. Market Revenue and Volume Forecast, by End Use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Material
11.5.5.2. Market Revenue and Volume Forecast, by Drug
11.5.5.3. Market Revenue and Volume Forecast, by End Use
12.1. Biotronik
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Meril Life Sciences Pvt. Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Elixir Medical
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Arterial Remodeling Technologies SA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. REVA Medical, LLC
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Arterial Remodeling Technologies SA
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. LEPU Medical
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Microport Scientific Corporation
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. LifeTech Scientific
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Abbott Laboratories
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
